Non-small cell lung cancer
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: Confirmed as advanced NSCLC (stage IIIB–IV) by histopathological and/or cytological examination with at least one measurable and evaluable target lesion; No prior first-line anti-tumor treatment received; Negative for driver genes (EGFR mutation ALK fusion and ROS1 fusion are all negative); PD-L1 < 1%; Not suitable for chemotherapy combined with other systemic therapeutic drugs (including but not limited to anti-angiogenic targeted drugs) but eligible if receiving chemotherapy combined with radiotherapy; TCM syndrome differentiation consistent with qi-yin deficiency syndrome; Age = 18 years; Expected survival period = 3 months; Performance status score = 2; Voluntarily participate in the study with good compliance and sign the informed consent form.
Exclusion criteria
Exclusion criteria: Known allergy to the ingredients of the study drug; Pregnant or lactating women; Multiple brain metastases multiple bone metastases or multiple liver metastases which are expected to have a significant impact on the patient's survival; Currently participating in other drug clinical trials; Refusal to cooperate with follow-up; Other reasons deemed by the researcher as making the patient unsuitable for participation in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression Free Survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| 3-year survival rate;?Disease Control Rate?;TCM syndromes and symptoms;Adverse Event?;Quality of life ;1-year survival rate;Objective Response Rate?; | — |
Countries
CHINA
Contacts
Department of Oncology Longhua Hospital Shanghai University of Traditional Chinese Medicine Shanghai China